

1. Education

2002	Degree of MD-PhD, University of Lausanne: HIV drug resistance
1998	Federal Diploma of Medicine (MD), University of Lausanne
1997	Molecular virology certificate
1997	Faculty of Science, University of Lausanne: Molecular biology certificate
1995 – 1996	University of Bari, IT
1992 – 1998	Medical School, University of Lausanne



2. Postgraduate formation

Current Position	CHUV Medical Oncology Service Chief – Full Professor – Chair of Thoracic Oncology, Head Medical Oncology (Cheffe de Service), Oncology Department, University Hospital of Lausanne (CHUV)
2009 – 2015	Chief Resident in charge of thoracic malignancies, Oncology Department, University Hospital of Lausanne (CHUV)
2013	Academic grade: Privat Doctent and Maitre d'Enseignement et Recherche (PD-MER1)
2009	Nomination as Senior physician ("Médecin Associé") at the University Hospital of Lausanne
2006	SSMO (Swiss Society of Medical Oncology), oral exam
2006	ESMO (European Society of Medical Oncology) exam in oncology (renewed in 2012 and 2017). MORA recertification in 2017 and 2022.
2006/2010/2012/2021	Training and certification in "Good Clinical Practices for investigators and study coordinators" (Swissmedic level 1-3), yearly from 2018
2006	Training in communication "Mieux communiquer" (Ligue suisse contre le cancer)
2005	Multidisciplinary Oncology Center, University Hospital of Lausanne, Fellowship
2002 – 2005	Internal Medicine Department, University Hospital of Lausanne, Residency in Internal Medicine (Oct 2002–Oct 2003 Multidisciplinary Oncology Centre)

3. Teaching activities

2008 –	In charge of whole medical and thoracic malignancy and part of general oncology education/teaching at the Faculty of Biology and Medicine of Lausanne, Switzerland
2008 –	Multidisciplinary regional teaching in general/thoracic oncology (E.g. Espace Compétences (nurses), Swiss & German Societies of pathology, Groupement des Oncologues Genevois)
2008 –	Teacher in educational programs in Switzerland (SAKK, SAMO, Forome), for national oncology societies (Netherlands, Greece, France, Italy, Spain, Denmark, Sweden, Japan, China, Brazil,...) and internationally on behalf of ASCO, BTOG, CECOG, ECCO, ESMO, ESO, ESTRO, ESTS, and IASLC.

4. Selected memberships and officer in societies

	ESMO (European Society for Medical Oncology)
2023 – 2025	- Past President
2020 – 2022	- President
2020 – 2022	- ESMO congresses President : Annual meeting (30K delegates), ESMO Asia, ESMO immunotherapy
2013 – 2019	- ESMO clinical guidelines editor/chair for thoracic malignancies
2018	- ESMO Congress 2018 Scientific chair
2016	- ELCC 2016 Scientific chair
2014 – 2020	- Women for Oncology Task Force / Committee chair
2014 –	- Executive Board of Directors member, communication chair
2013 – 2014	- Elected National representative
2012 – 2014	- E-Learning and CME Working Group (ECWG) member
2012 –	- Faculty member
	ICF (International Cancer Foundation)
2021 –	- President
	IASLC (International Association for the Study of Lung Cancer)
2014 –	- Publication Committee member
2013 – 2017	- Elected Board of Directors member
	ETOP (European Thoracic Oncology Platform) & ETOP/IBCSG Partners
2016 –	- Foundation Council Member
2012 –	- Scientific Coordinator /Scientific Comitee Chair (since 2021)
2011 –	- Chair of Information & Communication Committee
	SAMO (Swiss Academy of Multidisciplinary Oncology)
2022 –	- SAMO President
2019 – 2021	- SAMO Vice-President
2017 –	- SAMO Board member

2010 – - SAMO Lung Co-Chair (annual meetings)

Swiss Cancer League

2025 or 2027 - **Proposed President**

2023 – - Vice-President

2017 – - Board member

Fondazione San Salvatore

2023 – - **Chair of the Scientific Committee**

2018 – - Scientific Committee member

RHU PIONeer

2019 – - **Scientific Advisory Board Member**

PREVALUNG-EU

2023 – - **Scientific Advisory Board Member**

Paris Saclay Cancer Cluster Association

2023 – - **President of the Scientific Advisory Board**

2023 – **Galenica SA**

- **Board member**

Research grants

Peters as trial PI/international (co)Chair (steering committees not included; list non exhaustive)

2022 – **Scientific chair of ETOP/IBCSG Partners for thoracic malignancies. Funding co-responsibilities for all clinical trial grants, over 100 mio CHF/year**

2020 – 2022 Swiss Cancer Research KLS-455-08-2018: Characterization of sugar usage by pro-tumor neutrophils in lung cancer
2019 – Astrazeneca-sponsored MERMAID-2 trial: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III NSCLC

2019 – Astrazeneca-sponsored MERMAID-1 trial: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III NSCLC

2020 – GSK-sponsored ZEAL-1 trial: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic NSCLC

2020 – Roche-sponsored SKYSCAPER1 trial: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected NSCLC

2020 – MSD-sponsored ETOP/EORTC PEARLS trial: Study of Pembrolizumab (MK-3475) vs Placebo for Participants With NSCLC After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

2019 – Astrazeneca-sponsored MYSTIC trial: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in NSCLC

2019 – Roche-sponsored IPSOS trial: A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic NSCLC Who Are Deemed Unsuited For Platinum-Doublet Chemotherapy (IPSOS)

2018 – Roche-sponsored BFAST trial: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With NSCLC (B-FAST)

2017 – BMS-sponsored CheckMate 743 trial: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

2017 – NIVOTHYM ETOP and EORTC sponsored trial (immunotherapy for thymic carcinoma)

2018 – BEAT Mesothelioma ETOP sponsored trial (chemotherapy, immunotherapy and bevacizumab)

2017 – BOOSTER (EGFR positive osimertinib/bevacizumab NSCLC) ETOP sponsored trial

2016 – PEARLS MSD sponsored trial in collaboration with ETOP (PI: Peters) and EORTC, adjuvant immunotherapy in NSCLC. Lausanne as central research laboratory

2015 – Roche-sponsored ALEX trial: A Study Comparing Alectinib With Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase-Positive Advanced NSCLC Participants (ALEX)

2015 – 2017 Swiss Cancer Research KFS-3458-08-2014: Role of RANK signaling in non-small cell lung cancer

2014 – SPECTALung (Screening patients with thoracic tumors for efficient clinical trial access), EORTC/ETOP sponsored

2014 – NICOLAS (Nivolumab Consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC), ETOP sponsored

2014 – NICHE: Afatinib in NSCLC with HER2 mutation, ETOP sponsored

2014 – SPLENDOUR (Survival improvement in lung cancer induced by denosumab therapy), ETOP sponsored, EORTC coordinating group

2014 – Gateway Award (with Rising Tide Foundation) CATATeM: A Phase IB/II Study of Combination Treatment with Carboplatin/Paclitaxel and the Copper Chelator, Tetrathiomolybdate in Patients with Advanced Solid Tumors

2013 – STIMULI (Small cell lung cancer trial with ipilimumab in limited disease), ETOP sponsored

2013 Roche unrestricted grants: lung cancer risks factors, focusing on HIV

2012 – EMPHASIS (Erlotinib MALDI TOF phase III signature in squamous cell non-small cell lung cancer), ETOP sponsored

2012 – LUNGSCAPE, a project of ETOP, ETOP sponsored

2012 Award/Research grant Dr Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung (Krebsstiftung): ALK biology/RT-PCR

2009 – 2015 SAKK 16/08 trial: Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial

Peters as co-PI at the National Level /National Grants

2020 – 2023 **Oncosuisse grant KLS-4862-08-2019** : Harnessing the power of intravital microscopy to explore how the tumour vasculature modulates immune cell infiltration of malignant mesotheliomas and dissemination of cancer cells

2019 – **Oncosuisse AND-4905-01-2019** : Hopes and challenges of oncology in resource-limited countries

2017 – 2019 **Oncosuisse grant KFS-4401-02-2018** : Towards “second generation” communication trainings in cancer care: in search of meaningful outcome measures

2017 – 2019 **Oncosuisse grant KFS-4452-02-2018**: Role of Helicobacter Pylori infection in the response to cancer immunotherapy

2015 – 2017 **Swiss National Science Foundation 320030_160106**: Photo-Induction as a mean to improve cisplatin delivery to pleural malignancies: a clinical phase I and targeted phase II expansion cohort trial

2012 – **Oncosuisse grant KFS-3057-08-2012**: Notch signaling in lung squamous cell carcinoma

2011 – 2014 **Swiss national Science Foundation 320030-135197**: Low-dose photodynamic therapy selectively enhances liposomal doxorubicin uptake to superficially spreading pleural tumors

5. Editorial functions

2023 – **Deputy Editor Lung Cancer**

2020 – **Associate Editor Annals of Oncology**

2012 – 2020 **Deputy Editor: Journal of Thoracic Oncology**
Leading selection and transition to a new publisher in 2015/16

2013 – 2017 **ESMO guidelines editor** for thoracic malignancies

2012 – 2013 **ESMO guidelines co-editor** for thoracic malignancies

2013 – 2016 **Editor in Chief: Cancer Treatment Communications**

2013 – 2016 **Co-editor in Chief: Journal of Oncopathology**

2013 – **Co-Editor ESMO Thoracic Tumours essentials**

2014 – **Editorial board member**: European Medical Journal - Oncology

2013 – **Editorial board member**: Targeted Oncology

2013 – **Associate Editor**: Frontiers in Pharmacology and Anti-Cancer drug

2011 – 2012 **Associate Editor**: Lung Cancer

6. Publications

More than 400 publications in peer-review journals today
Current H score (65, total cite 22'225, web of science, May 2022)

7. Referee for scientific journals / grant reviews & Advisory roles

- Review editor: Frontiers in Thoracic Oncology
- Grant Reviewer for Swiss National Science Foundation (SNF)
- Grant Reviewer for the Swiss Cancer League Grants
- Grant Reviewer fond de dotation “Recherche en Santé Respiratoire” (France)
- Grant Reviewer and Scientific committee “Fondazione San Salvatore.
- Advisor National and Kapositrian University of Athens Member of Scientific Advisory Board on IMPRESS-Norway
- Stratgic Advisory Board of Paris Saclay Cancer (PSCC)
- Member of the Scientific Advisory Council of pharmaceutical industries: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecaner, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody.
- Permanent advisory board member for Framingham on lung cancer journal
- Reviewer in: New Engaln Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Thorax, Chest, European Respiratory Journal, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer, Cancer, Annals of Thoracic Surgery, Lung Cancer, Oncology, Radiation Oncology

8. Hobbies and public activities

- Competitive swimmer, currently very active in sport: running/swimming/ski

9. Political commitments

- Foundation Council President Ballet Béjart Lausanne (2018-)

- Head of main political group of the agglomeration for 8 years (2003–2011)
- Elected city parliament 4 times, active > 15 years since 1998
- Elected at National Parliament (2007)
- Member of « Le Passage » Foundation Council for 4 years (vulnerable populations) 2011–2015
- Elected President of « Centre de liaison des Associations Féminines Vaudoises (CLAFV) » for 4 years (2005–2009)
- External advisor for Swiss cancer plan 2018